Clinical DevelopmentNiyad, the nafamostat-based anticoagulant being developed by Talphera, has been evaluated extensively overseas and was found to be efficacious and safe, supporting its development.
FinancingThe recent capital raise removes the financing overhang regarding Talphera’s ability to complete the Phase 3 trial and modestly de-risks the company.
Investment OpportunityThe financing establishes an attractive exit opportunity for Talphera shareholders, with the potential acquisition by CorMedix following the primary endpoint readout.